Two cases of chronic graft-versus-host disease with elevated levels of soluble Fas ligand in serum.
It has recently been shown that the Fas-Fas ligand (FasL) system may be one of the pathogeneses for acute graft-versus-host disease (GVHD), and it has been reported that serum soluble Fas ligand (sFasL) increases with the presence of acute GVHD. However, there is no report on a correlation between the Fas-FasL system and chronic GVHD. We present two cases of chronic GVHD with elevated levels of serum sFasL. Its level in each case was high at the onset of chronic GVHD, but it decreased with steroid therapy. Liver dysfunction also improved as the level of serum sFasL decreased. It appears in these cases that the Fas-FasL system was related to the pathogenesis of liver damage.
Takada
S
S
Department of Internal Medicine, Saiseikai Maebashi Hospital, Maebashi City, Japan.
Hatsumi
N
N
Saito
T
T
Matsushima
T
T
Sakura
T
T
Tamura
J
J
Karasawa
M
M
Miyawaki
S
S
D000293:Adolescent; D002908:Chronic Disease; D016572:Cyclosporine / Q000627:therapeutic use; D053222:Fas Ligand Protein; D005260:Female; D006086:Graft vs Host Disease / Q000097:blood* / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008099:Liver / Q000503:physiopathology; D008297:Male; D008562:Membrane Glycoproteins / Q000097:blood*; D008875:Middle Aged; D011239:Prednisolone / Q000627:therapeutic use; D012995:Solubility
C505661:FASLG protein, human; D053222:Fas Ligand Protein; D007166:Immunosuppressive Agents; D008562:Membrane Glycoproteins; D016572:Cyclosporine; D011239:Prednisolone